NO20082704L - Hepatitt C virusvarianter - Google Patents

Hepatitt C virusvarianter

Info

Publication number
NO20082704L
NO20082704L NO20082704A NO20082704A NO20082704L NO 20082704 L NO20082704 L NO 20082704L NO 20082704 A NO20082704 A NO 20082704A NO 20082704 A NO20082704 A NO 20082704A NO 20082704 L NO20082704 L NO 20082704L
Authority
NO
Norway
Prior art keywords
variants
hepatitis
virus variants
methods
hcv
Prior art date
Application number
NO20082704A
Other languages
English (en)
Inventor
Chao Lin
Tara Kieffer
Christoph Sarrazin
Ann Kwong
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20082704L publication Critical patent/NO20082704L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Foreliggende oppfinnelse vedrører HCV-varianter, spesielt varianter som er resistente mot en proteaseinhibitorer så som VX-950. Dessuten tilveiebringes metoder og sammensetninger som er relatert til HCV-variantene. Videre tilveiebringes metoder for å isolere, identifisere og karakterisere multiple virale varianter fra en pasient.
NO20082704A 2005-11-11 2008-06-11 Hepatitt C virusvarianter NO20082704L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73557705P 2005-11-11 2005-11-11
US85459806P 2006-10-25 2006-10-25
PCT/US2006/044363 WO2007059221A2 (en) 2005-11-11 2006-11-13 Hepatitis c virus variants

Publications (1)

Publication Number Publication Date
NO20082704L true NO20082704L (no) 2008-08-11

Family

ID=38049275

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082704A NO20082704L (no) 2005-11-11 2008-06-11 Hepatitt C virusvarianter

Country Status (10)

Country Link
EP (4) EP2392588A3 (no)
JP (3) JP5409008B2 (no)
KR (2) KR20140098867A (no)
CN (1) CN101405295A (no)
AU (1) AU2006315438A1 (no)
CA (1) CA2629343A1 (no)
NO (1) NO20082704L (no)
NZ (1) NZ568324A (no)
RU (2) RU2008123606A (no)
WO (1) WO2007059221A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5409008B2 (ja) * 2005-11-11 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス改変体
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8809265B2 (en) 2011-10-21 2014-08-19 Abbvie Inc. Methods for treating HCV
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2019070854A1 (en) 2017-10-03 2019-04-11 Abbott Molecular Inc. ASSAY FOR DETECTION OF HEPATITIS C VIRUS (HCV)

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR900494A (fr) 1942-12-07 1945-06-29 Brown Procédé pour le fonctionnement d'une installation de conditionnement de l'air pourbancs d'essai en altitude
FR900483A (fr) 1942-12-22 1945-06-29 Fides Gmbh Variomètre électrique à inductance commandée par système excitateur réglable avec entre ses pôles au moins deux enroulements d'inductance variable
US2429215A (en) 1943-01-16 1947-10-21 Jarvis C Marble Turbine blade
US4835168A (en) 1985-12-16 1989-05-30 Eli Lilly And Company Thiadiazole antiviral agents
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
DE4123304C2 (de) 1991-07-13 1994-07-07 Jagenberg Ag Führungskopf für schwere Wickelrollen
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
CA2170020C (en) 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
EP0902782A1 (en) 1996-04-23 1999-03-24 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
US6127422A (en) 1996-05-06 2000-10-03 Eli Lilly And Company Anti-viral method
WO1997043310A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
EP0962527B1 (en) 1996-10-17 2004-08-04 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
PL194025B1 (pl) 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
EP1712623B1 (en) 1997-01-21 2011-10-19 The General Hospital Corporation Selection of proteins using RNA-protein fusions
CA2282398A1 (en) 1997-03-14 1998-09-17 Steven M. Ronkin Inhibitors of impdh enzyme
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
EP1003775B1 (en) 1997-08-11 2005-03-16 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
WO1999007734A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
AU1416099A (en) 1997-11-28 1999-06-16 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
EP1066247B1 (en) 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AU4855299A (en) * 1998-07-02 2000-01-24 University Of Florida Ns4a-ns3 catalytic domain of hepatitis c
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
KR100652535B1 (ko) 1999-03-19 2006-12-01 버텍스 파마슈티칼스 인코포레이티드 Ｉｍｐｄｈ 효소의 억제제
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
DK1177211T3 (da) 1999-05-04 2008-06-02 Boehringer Ingelheim Ca Ltd Surrogatcellebaseret system og fremgangsmåde til at analysere aktiviteten for Hepatitis C-virus NS3-protease
CA2376961A1 (en) 1999-07-26 2001-02-01 Bristol-Myers Squibb Pharma Company Lactam inhibitors of hepatitis c virus ns3 protease
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
JP2003525294A (ja) 2000-02-29 2003-08-26 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害剤
IL152022A0 (en) 2000-04-03 2003-04-10 Vertex Pharma Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
RU2002129564A (ru) 2000-04-05 2004-05-10 Шеринг Корпорейшн (US) Макроциклические ингибиторы сериновой ns3-протеазы, включающие n-циклические р2 структурные элементы вируса гепатита с
IL151935A0 (en) 2000-04-19 2003-04-10 Schering Corp Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
WO2001081359A1 (en) 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
CA2410682A1 (en) 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
KR100939155B1 (ko) 2000-07-21 2010-01-28 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제 억제제로서의신규한 펩티드
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
EP1337550B1 (en) 2000-11-20 2006-05-24 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
DE60138567D1 (de) 2000-12-12 2009-06-10 Schering Corp Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
ITRM20010336A1 (it) 2001-06-13 2002-12-13 Biostrands S R L Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
US6903126B2 (en) 2001-07-09 2005-06-07 Schering Ag 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
WO2003006490A1 (en) 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
CN100352819C (zh) 2002-01-23 2007-12-05 先灵公司 作为ns3－丝氨酸蛋白酶抑制剂的脯氨酸化合物用于制备治疗丙型肝炎病毒感染的药物
US6962932B2 (en) 2002-02-15 2005-11-08 Schering Aktiengesellschaft 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
KR20110028665A (ko) 2002-04-11 2011-03-21 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｃ형 간염 바이러스 ｎｓ3-ｎｓ4 프로테아제의 억제제
NZ540292A (en) 2002-10-29 2006-09-29 Boehringer Ingelheim Int Novel inhibitor-resistant HCV NS3 protease comprising a mutated amino acid sequence
CA2515216A1 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
EP1613620A1 (en) 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ATE547412T1 (de) 2003-04-11 2012-03-15 Vertex Pharma Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
TW200523270A (en) 2003-07-18 2005-07-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
US7449447B2 (en) 2003-08-26 2008-11-11 Schering Corporation Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
US7592419B2 (en) 2003-09-26 2009-09-22 Schering Corporation Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
AU2004285019B9 (en) * 2003-10-27 2011-11-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
WO2005051980A1 (en) 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
WO2005058821A1 (en) 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
KR20070026394A (ko) 2004-02-27 2007-03-08 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3 세린 프로테아제 억제제로서사이클릭 ｐ4'ｓ를 지닌 신규한 케토아미드
RU2006134002A (ru) 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
WO2005087730A1 (en) 2004-02-27 2005-09-22 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
AR049635A1 (es) 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
WO2006112482A1 (ja) * 2005-04-19 2006-10-26 Green Peptide Co., Ltd. Ｃ型肝炎ウイルス感染に関連する肝疾患の予後の予測
US7968697B2 (en) * 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
JP5409008B2 (ja) * 2005-11-11 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス改変体

Also Published As

Publication number Publication date
EP2392589A2 (en) 2011-12-07
RU2012121884A (ru) 2013-11-27
RU2008123606A (ru) 2009-12-20
NZ568324A (en) 2012-01-12
WO2007059221A2 (en) 2007-05-24
JP2009515532A (ja) 2009-04-16
EP2392588A3 (en) 2012-03-07
CA2629343A1 (en) 2007-05-24
AU2006315438A2 (en) 2008-09-25
WO2007059221A9 (en) 2007-08-23
EP2392588A2 (en) 2011-12-07
EP2392589A3 (en) 2012-06-20
JP2014217390A (ja) 2014-11-20
JP2012196230A (ja) 2012-10-18
EP1951748A2 (en) 2008-08-06
KR20140098867A (ko) 2014-08-08
KR20080072906A (ko) 2008-08-07
EP2392590A3 (en) 2012-03-14
EP2392590A2 (en) 2011-12-07
AU2006315438A1 (en) 2007-05-24
JP5409008B2 (ja) 2014-02-05
CN101405295A (zh) 2009-04-08
WO2007059221A3 (en) 2007-12-06
EP1951748B1 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
NO20075616L (no) Tripeptider som hepatitt C virus inhibitorer
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
NO20082704L (no) Hepatitt C virusvarianter
MX2009004943A (es) Inhibidores del virus de la hepatitis c.
WO2008008776A3 (en) Hepatitis c virus inhibitors
ATE492558T1 (de) Makrocyclische peptide als hepatitis-c-virus- hemmer
ATE492559T1 (de) Makrocyclische peptide als hepatitis-c-virus- hemmer
ATE474827T1 (de) Hcv-replikationshemmer
DK1924593T3 (da) HCV NS3-proteaseinhibitorer
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
HK1126486A1 (en) Hepatitis c virus inhibitors (hcv)
NO20081086L (no) Makrosykliske peptider som HCV NS3-proteaseinhibitorer
NO20076355L (no) Dengue serotype 1 attenuert stamme
EP1879607A4 (en) INHIBITORS OF HCV NS3 PROTEASE
NO20070751L (no) Inhibitorer av HCV-replifikasjon
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
NO20091706L (no) Inhibitorer av hepatitt C virus
TW200720285A (en) Nucleoside compounds for treating viral infections
NO20076360L (no) Dengue serotype 2 attenuert stamme
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
TW200640474A (en) Tricyclic-nucleoside compounds for treating viral infections
NO20081127L (no) Vaksinering mot Dengue virusinfeksjon
ZA200800072B (en) HCV NS3 Protease inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application